nach oben

Clinical and Experimental Medicine

Erschienen in:

05.06.2020 | Review Article

The diagnostic and prognostic value of exosome-derived long non-coding RNAs in cancer patients: a meta-analysis

verfasst von: Huiwen Mu, Sujie Zhang, Zhaoying Yao, Yunxin Liu, Kang Lin, Zheng Zhao, Yubing Zhu

Erschienen in: Clinical and Experimental Medicine | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Exosome-derived long non-coding RNAs (lncRNAs) as novel biomarkers are widely investigated in various cancers, yet results remain controversial. The aim of this meta-analysis was to clarify the diagnostic and prognostic value of exosome-derived lncRNAs in cancer.

Methods

PubMed, Web of Science, EMBASE, CNKI, and WanFang online databases were comprehensively searched for eligible studies up to January, 2020. To evaluate the diagnostic effect, sensitivity, specificity, and area under the curve (AUC) were pooled. Threshold effect, subgroup analysis, and meta-regression were applied to explore heterogeneity. Deeks’ funnel plot and sensitivity analysis were used to examine publication bias and stability of meta-analysis, respectively. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) and recurrence free survival (RFS) were calculated to assess the prognostic value.

Results

A total of 29 eligible studies involving 3882 patients were enrolled in the meta-analysis, which included 26 on diagnosis and 11 on prognosis. For diagnosis analysis, the pooled sensitivity, specificity, and AUC were 0.83 (95% CI 0.78–0.87), 0.80 (95% CI 0.75–0.84), and 0.88 (95% CI 0.85–0.91), respectively. Meta-regression revealed that the cancer type acted as the potential source of heterogeneity. Sensitivity analysis and Deeks’ funnel plot indicated that results were relatively robust and had no publication bias. For the prognosis analysis, results suggested that overexpression of exosome-derived lncRNAs which upregulated in cancer showed a significant association with poor OS (HR 2.21, 95% CI 1.79–2.71, p < 0.001). Conversely, overexpression of exosome-derived lncRNAs which downregulated in cancer was markedly related to better OS (HR 0.28, 95% CI 0.14–0.55, p < 0.001).

Conclusion

This meta-analysis reveals that exosome-derived lncRNAs might serve as promising diagnostic and prognostic biomarkers for cancer. However, the clinical value of exosome-derived lncRNAs needs to be further confirmed.

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.CrossRef

Higginson J. The international agency for research on cancer: a brief review of its history, mission, and program. Toxicol Sci. 1998;43:79–85.PubMed

Zheng J, Ye X, Liu Y, Zhao Y, He M, Xiao H. The combination of CTCs and CEA can help guide the management of patients with SPNs suspected of being lung cancer. BMC Cancer BMC Cancer. 2020;20:1–8.

Chen C, Chen Q, Zhao Q, Liu M, Guo J. Value of combined detection of serum CEA, CA72-4, CA19-9, CA15-3 and CA12-5 in the diagnosis of gastric cancer. Ann Clin Lab Sci. 2017;47:260–3.PubMed

Edoo MIA, Chutturghoon VK, Wusu-Ansah GK, Zhu H, Zhen TY, Xie HY, et al. Serum biomarkers AFP, CEA and CA19-9 combined detection for early diagnosis of hepatocellular carcinoma. Iran J Public Health. 2019;48:314–22.PubMedPubMedCentral

Kalluri R. The biology and function of exosomes in cancer. J Clin Investig. 2016;126:1208–15.PubMed

Chen R, Xu X, Qian Z, Zhang C, Niu Y, Wang Z, et al. The biological functions and clinical applications of exosomes in lung cancer. Cell Mol Life Sci [Internet]. 2019;76:4613–33. https://doi.org/10.1007/s00018-019-03233-y.CrossRef

Filella X, Foj L. Prostate cancer detection and prognosis: From prostate specific antigen (PSA) to exosomal biomarkers. Int J Mol Sci. 2016;17:1784.PubMedCentral

Lässer C. Exosomes in diagnostic and therapeutic applications: Biomarker, vaccine and RNA interference delivery vehicle. Expert Opin Biol Ther. 2015;15:103–17.PubMed

10.

Tucci M, Mannavola F, Passarelli A, Stucci LS, Cives M, Silvestris F. Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity. Oncotarget. 2018;9:20826–37.PubMedPubMedCentral

11.

Mannavola F, Pezzicoli G, Tucci M. DLC-1 down-regulation via exosomal miR-106b-3p exchange promotes CRC metastasis by the epithelial-to-mesenchymal transition. Clin Sci. 2020;134:955–9.PubMed

12.

Wu K, Xing F, Wu S, Watabe K. BBA—reviews on cancer extracellular vesicles as emerging targets in cancer: recent development from bench to bedside. BBA Rev Cancer [Internet]. 2017;1868:538–63. https://doi.org/10.1016/j.bbcan.2017.10.001.CrossRef

13.

Gareev I, Beylerli O, Yang G, Sun J, Pavlov V, Izmailov A, et al. The current state of MiRNAs as biomarkers and therapeutic tools. Clin Exp Med [Internet]. 2020. https://doi.org/10.1007/s10238-020-00627-2.CrossRef

14.

Kuang M, Peng Y, Tao X, Zhou Z, Mao H, Zhuge L, et al. FGB and FGG derived from plasma exosomes as potential biomarkers to distinguish benign from malignant pulmonary nodules. Clin Exp Med [Internet]. 2019;19:557–64. https://doi.org/10.1007/s10238-019-00581-8.CrossRef

15.

St. Laurent G, Wahlestedt C, Kapranov P. The Landscape of long noncoding RNA classification. Trends Genet. 2015;31:239–51. https://doi.org/10.1016/j.tig.2015.03.007.CrossRefPubMedPubMedCentral

16.

Wang F, Xie C, Zhao W, Deng Z, Yang H, Fang Q. Long non-coding RNA CARLo-5 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Clin Exp Med. 2017;17:33–43.PubMed

17.

Hu X, Sood AK, Dang CV, Zhang L. The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev. 2018;48:8–15.PubMed

18.

Whiteside TL. The potential of tumor-derived exosomes for noninvasive cancer monitoring: an update. Expert Rev Mol Diagn. 2018;18:1029–40. https://doi.org/10.1080/14737159.2018.1544494.CrossRefPubMedPubMedCentral

19.

Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:332–6.

20.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:1–16.

21.

Margulis AV, Pladevall M, Riera-guardia N, et al. Quality assessment of observational studies in a drug-safety systematic review, Comparison of two tools: the Newcastle-Ottawa scale and the RTI item bank. Clin Epidemiol. 2014;6:981–93.

22.

Reitsma JB, Glas AS, Rutjes AWS, Scholten RJPM, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58:982–90.PubMed

23.

Melsen WG, Bootsma MCJ, Rovers MM, Bonten MJM. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. Clin Microbiol Infect. 2014;20:123–9.PubMed

24.

DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45:139–45. https://doi.org/10.1016/j.cct.2015.09.002.CrossRefPubMedPubMedCentral

25.

Oehme F, Krahl S, Gyorffy B, et al. Low level of exosomal long non-coding RNA HOTTIP is a prognostic biomarker in colorectal cancer. RNA Biol. 2019;16:1339–455. https://doi.org/10.1080/15476286.2019.1637697.CrossRefPubMedPubMedCentral

26.

Lee YR, Kim G, Tak WY, et al. Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma. Int J Cancer. 2019;144:1444–522.PubMed

27.

Wang B, Wang YZ, Wang K, Ji TL, Cui BZ, He YY. Expression and clinical significance of lncRNA LINC00511 in plasma exosome of glioma patients. Chin J Pract Nerv Dis. 2019;144:1444–522.

28.

Ren XF, Li ZH. Expression and clinical significance of exosomal long non-coding RNA CCAT1 in pancreatic cancer. Lingnan Mod Clin Surg. 2019;19:23–7.

29.

Wang J, Yang K, Yuan W, Gao Z. Determination of serum exosomal h19 as a noninvasive biomarker for bladder cancer diagnosis and prognosis. Med Sci Monit. 2018;24:9307–16.PubMedPubMedCentral

30.

Xu H, Chen Y, Dong X, Wang X. Serum exosomal long noncoding RNAs ENSG00000258332.1 and LINC00635 for the diagnosis and prognosis of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2018;27:710–6.PubMed

31.

Liu L, Meng T, Yang XH, et al. Prognostic and predictive value of long non-coding RNA GAS5 and mircoRNA-221 in colorectal cancer and their effects on colorectal cancer cell proliferation, migration and invasion. Cancer Biomarkers. 2018;22:283–99.PubMed

32.

Zhan Y, Du L, Wang L, et al. Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis. Mol Cancer. 2018;17:1–5.

33.

Liu T, Zhang X, Gao S, et al. Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer. Oncotarget. 2016;7:85551–633.PubMedPubMedCentral

34.

Wu F, Wang CX, Tian H. Expression and clinical significance of LncRNA ZFAS1 in serum exosomes of patients with hepatocellular carcinoma. Chin J Cancer Prev Treatm. 2019;12:849–54.

35.

Zhang S, Du L, Wang L, et al. Evaluation of serum exosomal LncRNA-based biomarker panel for diagnosis and recurrence prediction of bladder cancer. J Cell Mol Med. 2019;23:1396–405.PubMed

36.

Li S, Zhang M, Zhang H, et al. Exosomal long noncoding RNA lnc-GNAQ-6:1 may serve as a diagnostic marker for gastric cancer. Clin Chim Acta. 2020;501:252–7. https://doi.org/10.1016/j.cca.2019.10.047.CrossRefPubMed

37.

Wang YH, Ji J, Wang BC, et al. Tumor-derived exosomal long noncoding RNAs as promising diagnostic biomarkers for prostate cancer. Cell Physiol Biochem. 2018;46:532–45.PubMed

38.

Yazarlou F, Modarressi MH, Mowla SJ, et al. Urinary exosomal expression of long non-coding RNAs as diagnostic marker in bladder cancer. Cancer Manag Res. 2018;10:6357–65.PubMedPubMedCentral

39.

Lin Y, Tao H. Diagnostic value of plasma exosomal lncRNA H19 for breast cancer. Chin J Clin Lab Sci. 2018;036(002):99–101.

40.

Wang J, Zhou Y, Lu J, et al. Combined detection of serum exosomal miR-21 and HOTAIR as diagnostic and prognostic biomarkers for laryngeal squamous cell carcinoma. Med Oncol. 2014;31:1–8.

41.

Zheng R, Du M, Wang X, et al. Exosome-transmitted long non-coding RNA PTENP1 suppresses bladder cancer progression. Mol Cancer. 2018;17:1–13.

42.

Li C, Lv Y, Shao C, et al. Tumor-derived exosomal lncRNA GAS5 as a biomarker for early-stage non-small-cell lung cancer diagnosis. J Cell Physiol. 2019;234:20721–7.PubMed

43.

Lin LY, Yang L, Zeng Q, et al. Tumor-originated exosomal lncUEGC1 as a circulating biomarker for early-stage gastric cancer. Mol Cancer. 2018;17:1–6.

44.

Zhang R, Xia Y, Wang Z, et al. Serum long non coding RNA MALAT-1 protected by exosomes is up-regulated and promotes cell proliferation and migration in non-small cell lung cancer. Biochem Biophys Res Commun. 2017;490:406–14. https://doi.org/10.1016/j.bbrc.2017.06.055.CrossRefPubMed

45.

Işin M, Uysaler E, Özgür E, et al. Exosomal lncRNA-p21 levels may help to distinguish prostate cancer from benign disease. Front Genet. 2015;6:168.PubMedPubMedCentral

46.

Cai C, Zhang H, Zhu Y, et al. Serum exosomal long noncoding RNA Pcsk2-2:1 as a potential novel diagnostic biomarker for gastric cancer. Oncol Targets Ther. 2019;12:10035–41.

47.

Zhao R, Zhang Y, Zhang X, et al. Exosomal long noncoding RNA HOTTIP as potential novel diagnostic and prognostic biomarker test for gastric cancer. Mol Cancer. 2018;17:1–5.

48.

Pan L, Liang W, Fu M, et al. Exosomes-mediated transfer of long noncoding RNA ZFAS1 promotes gastric cancer progression. J Cancer Res Clin Oncol. 2017;143:991–1004.PubMed

49.

Lin Y, Tao H. Diagnostic value of plasma exosomal lncRNA MALAT1 for breast cancer. J Luzhou Med Coll. 2012;41:3662–3.

50.

Zhang HL, Cai CC, Zhang MM, et al. Expression and screening value of serum exosomes derived long-non coding RNA RPN2-4 in gastric cancer. Chin J Clin Lab Sci. 2019;37(05):331–3.

51.

Teng Y, Kang H, Chu Y. Identification of an exosomal long noncoding RNA sox2-ot in plasma as a promising biomarker for lung squamous cell carcinoma. Genet Test Mol Biomarkers. 2019;23:235–40.PubMed

52.

Abd El Gwad A, Matboli M, El-Tawdi A, et al. Role of exosomal competing endogenous RNA in patients with hepatocellular carcinoma. J Cell Biochem. 2018;119:8600–10.PubMed

53.

Barbagallo C, Brex D, Caponnetto A, et al. LncRNA UCA1, upregulated in CRC biopsies and downregulated in serum exosomes, controls mRNA expression by RNA–RNA interactions. Mol Ther Nucleic Acids. 2018;12:229–41. https://doi.org/10.1016/j.omtn.2018.05.009.CrossRefPubMedPubMedCentral

54.

Wu Y, Wang Y, Wei M, Han X, Xu T, Cui M. Advances in the study of exosomal lncRNAs in tumors and the selection of research methods. Biomed Pharmacother [Internet]. 2020;123:109716. https://doi.org/10.1016/j.biopha.2019.109716.CrossRefPubMed

55.

Hu Q-Y, Zhao Z-Y, Li S-Q, Li L, Li G-K. A meta-analysis: the diagnostic values of long non-coding RNA as a biomarker for gastric cancer. Mol Clin Oncol. 2017;6:846–52.PubMedPubMedCentral

56.

Cai J, Zuo X, Chen Z, et al. Long noncoding RNAs serve as potential diagnostic biomarkers for colorectal cancer. J Cancer. 2019;10:611–9.PubMedPubMedCentral

57.

Quan J, Pan X, Zhao L, et al. LncRNA as a diagnostic and prognostic biomarker in bladder cancer: a systematic review and meta-analysis. Oncol Targets Ther. 2018;11:6415–24.

58.

Kang W, Zheng Q, Lei J, Chen C, Yu C. Prognostic value of long noncoding RNAs in patients with gastrointestinal cancer: A systematic review and meta-analysis. Dis Markers. 2018;2018.

59.

Shi SJ, Wang LJ, Yu B, Li YH, Jin Y, Bai XZ. LncRNA-ATB promotes trastuzumab resistance and invasionmetastasis cascade in breast cancer. Oncotarget. 2015;6:11652–63.PubMedPubMedCentral

60.

Kalra H, Adda CG, Liem M, Ang C, Mechler A, Simpson RJ, et al. Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics. 2013;13:3354–64.PubMed

Titel: The diagnostic and prognostic value of exosome-derived long non-coding RNAs in cancer patients: a meta-analysis
verfasst von: Huiwen Mu
Sujie Zhang
Zhaoying Yao
Yunxin Liu
Kang Lin
Zheng Zhao
Yubing Zhu
Publikationsdatum: 05.06.2020
Verlag: Springer International Publishing
Erschienen in: Clinical and Experimental Medicine / Ausgabe 3/2020
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI: https://doi.org/10.1007/s10238-020-00638-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The diagnostic and prognostic value of exosome-derived long non-coding RNAs in cancer patients: a meta-analysis

Abstract

Purpose

Methods

Results

Conclusion

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Nierenultraschall: Tipps vom Profi

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

IL-10 suppresses IFN-γ-mediated signaling in lung adenocarcinoma

The association of neutrophil-to-lymphocyte ratio with all-cause mortality in Chinese patients with MPO-ANCA associated vasculitis

Role Of TP53 mutations in predicting the clinical efficacy of hypomethylating therapy in patients with myelodysplastic syndrome and related neoplasms: a systematic review and meta-analysis

Six long noncoding RNAs as potentially biomarkers involved in competitive endogenous RNA of hepatocellular carcinoma

Cross-sectional associations between angiotensin-converting enzyme inhibitor use and cancer diagnosis in US adults

HCV infection and non-Hodgkin lymphomas: an evolving story

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Nierenultraschall: Tipps vom Profi

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Update Innere Medizin